Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 in recurrent/refractory malignant lymphoma
NCT04477772Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of tifcemalimab in malignant lymphoma, sponsored by Shanghai Junshi Biosciences Co., Ltd. Started Jul 2020; status: completed.
02
Drugs
tifcemalimab
03
Conditions
malignant lymphoma
Beyond the preview
Go deeper on NCT04477772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477772.